Characterizing the Molecular Abnormalities in Rare De Novo Ph^＋ Acute Myeloid Leukemia  

作　　者：Hong-Ying Chao Guang-Ying Sheng Xiu-Wen Zhang Min Zhou Hong-Jie Shen Su-Ning Chen Jian-Nong Cen Yi-Wu Sun Tao Chen Xu-Zhang Lu Ri Zhang 

机构地区：[1]Department of Hematology, Affiliated Changzhou Second Hospital of Nanjing Medical University, Changzhou, Jiangsu 213003, China [2]Department of Hematology, The First Affiliated Hospital of Suzhou University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, Jiangsu 215006, China

出　　处：《Chinese Medical Journal》2018年第10期1246-1248,共3页中华医学杂志（英文版）

基　　金：This work was supported by grants from the National Natural Science funds （No. 81500103）, Natural Science Foundation of Jiangsu Province （BK-20151230）, and the high-level medical talents training project （No. 2016CZLJ027）.

摘　　要：To the Editor：The t（9;22）（q34;q 11） （Philadelphia chromosome [Ph]） balanced translocation results in fusion of the BCR gene at 22q11 with cytoplasmic tyrosine kinase gene ABL1 and plays an essential role in leukemic transformation.The Ph is an infrequent finding in de novo acute myeloid leukemia （AML）,approximately 0.5-3% of newly diagnosed patients. The World Health Organization （WHO） recently released a revised version of the Classification of Hematopoietic and Lymphoid Malignancies,a new provisional category of AM L with BCR-ABL1 was added to recognize these rare Ph AML cases that could benefit from tyrosine-kinase inhibitor （TKI） therapy. It is required to enlarge the sample size and research the molecular or genomic features to increase the argument in favor ofPh AML as a real entity.To the Editor：The t（9;22）（q34;q 11） （Philadelphia chromosome [Ph]） balanced translocation results in fusion of the BCR gene at 22q11 with cytoplasmic tyrosine kinase gene ABL1 and plays an essential role in leukemic transformation.The Ph is an infrequent finding in de novo acute myeloid leukemia （AML）,approximately 0.5-3% of newly diagnosed patients. The World Health Organization （WHO） recently released a revised version of the Classification of Hematopoietic and Lymphoid Malignancies,a new provisional category of AM L with BCR-ABL1 was added to recognize these rare Ph AML cases that could benefit from tyrosine-kinase inhibitor （TKI） therapy. It is required to enlarge the sample size and research the molecular or genomic features to increase the argument in favor ofPh AML as a real entity.

分 类 号：S858.237.4[农业科学—临床兽医学] X703[农业科学—兽医学]